Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Pollack

Showing results (81-90 of 265) with videos related to

Pageof 27
Sort By:
American Journal of Clinical Oncology|October 7, 2006
A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancerSteven J Feigenberg, Alexandra L Hanlon, Eric M Horwitz, et al.
International Journal of Radiation Oncology, Biology, Physics|July 29, 2010
Intensity Modulated Radiation Therapy Reduces Gastrointestinal Toxicity in Patients Treated with Androgen Deprivation Therapy for Prostate CancerNavesh K Sharma, Tianyu Li, David Y Chen, et al.
The Journal of Urology|May 29, 2003
Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy aloneEric M Horwitz, Robert G Uzzo, Alexandra L Hanlon, et al.
Scientific Reports|June 21, 2018
Plasmonic Optical Imaging of Gold Nanorods Localization in Small AnimalsKeying Xu, Junwei Shi, Ali Pourmand, et al.
International Journal of Radiation Oncology, Biology, Physics|May 13, 2008
Does treatment duration affect outcome after radiotherapy for prostate cancer?David J D'Ambrosio, Tianyu Li, Eric M Horwitz, et al.
Cancer|May 24, 2007
Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapyPeter B Morgan, Alexandra L Hanlon, Eric M Horwitz, et al.
International Journal of Radiation Oncology, Biology, Physics|May 14, 2013
A novel method for predicting late genitourinary toxicity after prostate radiation therapy and the need for age-based risk-adapted dose constraintsAwad A Ahmed, Brian Egleston, Pino Alcantara, et al.
Urology|August 2, 2003
Positive prostate biopsy laterality and implications for stagingMark K Buyyounouski, Eric M Horwitz, Alexandra L Hanlon, et al.
International Journal of Radiation Oncology, Biology, Physics|January 2, 2007
Radiation dose and late failures in prostate cancerPeter B Morgan, Alexandra L Hanlon, Eric M Horwitz, et al.
International Journal of Radiation Oncology, Biology, Physics|March 9, 2005
What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?Steven J Feigenberg, Alexandra L Hanlon, Eric M Horwitz, et al.
Pageof 27

Showing results (81-90 of 265) with videos related to

Sort By:
Pageof 27
American Journal of Clinical Oncology|October 7, 2006
A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancerSteven J Feigenberg, Alexandra L Hanlon, Eric M Horwitz, et al.
International Journal of Radiation Oncology, Biology, Physics|July 29, 2010
Intensity Modulated Radiation Therapy Reduces Gastrointestinal Toxicity in Patients Treated with Androgen Deprivation Therapy for Prostate CancerNavesh K Sharma, Tianyu Li, David Y Chen, et al.
The Journal of Urology|May 29, 2003
Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy aloneEric M Horwitz, Robert G Uzzo, Alexandra L Hanlon, et al.
Scientific Reports|June 21, 2018
Plasmonic Optical Imaging of Gold Nanorods Localization in Small AnimalsKeying Xu, Junwei Shi, Ali Pourmand, et al.
International Journal of Radiation Oncology, Biology, Physics|May 13, 2008
Does treatment duration affect outcome after radiotherapy for prostate cancer?David J D'Ambrosio, Tianyu Li, Eric M Horwitz, et al.
Cancer|May 24, 2007
Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapyPeter B Morgan, Alexandra L Hanlon, Eric M Horwitz, et al.
International Journal of Radiation Oncology, Biology, Physics|May 14, 2013
A novel method for predicting late genitourinary toxicity after prostate radiation therapy and the need for age-based risk-adapted dose constraintsAwad A Ahmed, Brian Egleston, Pino Alcantara, et al.
Urology|August 2, 2003
Positive prostate biopsy laterality and implications for stagingMark K Buyyounouski, Eric M Horwitz, Alexandra L Hanlon, et al.
International Journal of Radiation Oncology, Biology, Physics|January 2, 2007
Radiation dose and late failures in prostate cancerPeter B Morgan, Alexandra L Hanlon, Eric M Horwitz, et al.
International Journal of Radiation Oncology, Biology, Physics|March 9, 2005
What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?Steven J Feigenberg, Alexandra L Hanlon, Eric M Horwitz, et al.
Pageof 27